CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法：在肿瘤治疗中的疗效、不良反应、剂量限制性毒性与长期随访
英文原题：CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.
查看英文原题
CAR-T cell therapy: Efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已成为癌症治疗中突破性且极具前景的方法。本文综述 CAR-T 疗法治疗多种血液系统恶性肿瘤的疗效，并提及其在实体瘤中的作用；目前 CAR-T 尚未获 FDA 批准用于实体瘤。本文还讨论常见及少见副作用，并分别关注不同药物的影响。通过回顾 FDA 对 CAR-T 疗法研究的建议，我们全面讨论了剂量限制性毒性，进一步凸显制定精准剂量策略的必要性，以平衡治疗获益与潜在风险。此外，我们回顾了接受 CAR-T 疗法患者的长期随访，以深入了解疗效持久性及迟发效应。
展开英文摘要原文
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various hematological malignancies, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet.
Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities. This further highlights the need for precise dosing strategies, striking a balance between therapeutic benefits and potential risks.
Additionally, we reviewed the long-term follow-up of patients receiving CAR-T therapy to gain valuable insights into response durability and late-onset effects.
论文信息
- 作者
- Elmarasi M、Elkonaissi I、Elsabagh AA、Elsayed E、Elsayed A、Elsayed B、Elmakaty I、Yassin M
- 第一作者单位
- Department of Medical Education, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar.
- 通讯作者单位
- College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar; Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), P.O. Box 3050, Doha, Qatar. Electronic address: yassin@hamad.qa.
- 文献类型
- 综述
- 期刊
- International immunopharmacology2024 Jun 30
- 原文标识
- PubMed 38788449 · DOI 10.1016/j.intimp.2024.112312